Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial-Reference-Cited by-同舟云学术

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial

Published:2022-01-11 Issue:1 Volume:7 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Chen Cunte,Liu Si-Yang Maggie,Chen Yedan,Ou Qiuxiang^ORCID,Bao Hua,Xu Ling^ORCID,Zhang Yikai^ORCID,Zhong Wenzhao,Zhou Qing,Yang Xue-Ning^ORCID,Shao Yang^ORCID,Wu Yi-Long^ORCID,Liu Si-Yang^ORCID,Li Yangqiu^ORCID

Funder

National Natural Science Foundation of China

Guangdong Provincial Applied Science and Technology Research & Development Program

Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/152631/files/pdf

Reference58 articles.

1. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

2. Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade;Lee;JCI Insight,2020

3. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolated Monoclonal T-Cell Receptor Gene Rearrangement in a Lung Adenocarcinoma Harboring MET Exon 14 Skipping: Diagnostic Pitfall;International Journal of Surgical Pathology;2024-08-18

2. Exploring the potential of the TCR repertoire as a tumor biomarker (Review);Oncology Letters;2024-06-28

3. Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma;Journal for ImmunoTherapy of Cancer;2024-06

4. Increased co-expression of ICOS and PD-1 predicts poor overall survival in patients with acute myeloid leukemia;Immunobiology;2024-05

5. Immune effector dysfunction signatures predict outcomes in patients with colorectal cancer;International Immunopharmacology;2024-05